The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Globe Investor

News Sources

Take control of your investments with the latest investing news and analysis

Press release from PR Newswire

Questcor Pharmaceuticals to Present at Bank of America Merrill Lynch 2012 Health Care Conference

Monday, May 07, 2012

Questcor Pharmaceuticals to Present at Bank of America Merrill Lynch 2012 Health Care Conference06:30 EDT Monday, May 07, 2012ANAHEIM, Calif., May 7, 2012 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) announced today that executive management will present at the Bank of America Merrill Lynch 2012 Health Care Conference in Las Vegas on May 16, 2012 at 1:40 p.m. PT / 4:40 p.m. ET.A live webcast and subsequent archived replay of the presentation will be accessible at http://ir.questcor.com/events.cfm.  The replay will be available for approximately 90 days after the event.About Questcor                                                                                      Questcor Pharmaceuticals, Inc. is a biopharmaceutical company whose primary product helps patients with serious, difficult-to-treat medical conditions.  Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications.  Of these 19 indications, Questcor currently generates substantially all of its net sales from three indications: the treatment of proteinuria in idiopathic types of nephrotic syndrome, the treatment of acute exacerbations of multiple sclerosis in adults, and the treatment of infantile spasms in children under two years of age. With respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus."  Questcor is also currently planning to explore the potential initiation of a commercial effort in rheumatology, as Acthar is approved for several rheumatology-related conditions including Lupus, Dermatomyositis, Polymyositis and Rheumatoid Arthritis. Questcor is also exploring the possibility of developing markets for other on-label indications and the possibility of pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need.    For more information about Questcor, please visit www.questcor.com. SOURCE Questcor Pharmaceuticals, Inc.For further information: Investors, Gregory Gin, +1-646-445-4801, or Doug Sherk, +1-415-568-4887, or Media, Janine McCargo, +1-646-688-0425, all of EVC Group